Literature DB >> 14679073

Development and validation of radioligand binding assays to measure total, IgA, IgE, IgG, and IgM insulin antibodies in human serum.

MichaeI Moxness1, Jim Foley, Mark Stene, Deborah Finco-Kent, Vahe Bedian, Alan Krasner, Thomas Kawabata.   

Abstract

Radioligand binding assays for total and Ig classes of insulin antibodies (IAB) were developed and validated. For each assay, insulin-extracted serum samples were incubated with radiolabeled insulin in the presence and absence of high levels of unlabeled insulin to determine nonspecific binding and total binding, respectively. To measure total IAB, antibody-bound insulin was precipitated with a polyethylene glycol solution, washed, and counted in a gamma-counter. To measure IgG IAB, samples were treated with protein G-Sepharose beads, centrifuged, washed, and counted. For the measurement of IgA, IgE, and IgM IAB, IgG was removed from the samples and treated with anti-IgA, -IgE, or -IgM conjugated to Sepharose beads, centrifuged, washed, and counted. The acid/charcoal extraction of bound and unbound insulin from serum samples was optimized. Specificity and binding capacity of the protein G and antibody-bound beads were evaluated and optimized. The linear region of the total and IgG IAB assays was determined using serum samples containing high levels of insulin antibodies. The limit of quantitation, limit of detection, and precision for all the assays were also determined.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14679073     DOI: 10.1196/annals.1288.040

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  1 in total

1.  Gene CNVs and protein levels of complement C4A and C4B as novel biomarkers for partial disease remissions in new-onset type 1 diabetes patients.

Authors:  Suzanne E Kingery; Yee Ling Wu; Bi Zhou; Robert P Hoffman; C Yung Yu
Journal:  Pediatr Diabetes       Date:  2011-12-13       Impact factor: 4.866

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.